![Alert Sign](https://www.hackensackumc.org/wp-content/themes/hackensack-umc/images/exclamation-triangle.svg")
![Close Alert Box](https://www.hackensackumc.org/wp-content/themes/hackensack-umc/images/X.svg")
Physicians in the Lymphoma Division at John Theurer Cancer Center, part of Hackensack University Medical Center in New Jersey, treat hundreds of lymphoma patients every year.
Our team has been at the forefront of the development of many novel therapies—particularly those for mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, T-cell lymphomas, Hodgkin lymphoma, and chronic lymphocytic leukemia (CLL). When you come to us for your care, you benefit from highly subspecialized comprehensive high-quality care based on the findings of the latest medical research, as well as opportunities to participate in clinical trials of promising new therapies.
Treatment Based on the Biology of Your Cancer
Progress in understanding the biology of lymphoma has shown that they differ greatly at the molecular level, even if they look the same under the microscope. This explains also why they behave differently (for example, whether or not they respond to chemotherapy). There are over 100 distinct subtypes of lymphoma, and it imperative to get an accurate diagnosis and molecular analysis of your cancer to ensure you receive the most effective therapy. Our hematopathologists are exceptional and essential for helping your doctor to understand precisely the molecular features—and therefore behavior—of your disease to customize the type of therapy that you need.
Leaders in Bone Marrow Transplantation for Lymphoma
John Theurer Cancer Center has one of the largest stem cell transplantation programs in the country, including its use for lymphoma treatment, with over 1,500 stem cell transplantations performed since its inception. Through our relationship with the National Cancer Institute Immunology Branch, we have developed new approaches to prevent graft-versus-host disease after transplantation (a complication in which cells from the donor attack tissues of the recipient). We are currently the only center conducting a clinical trial of combined ipilimumab and nivolumab immunotherapy after transplantation to improve outcomes and reduce the risk of recurrence in patients with high-risk disease.
Partners in Lymphoma Education
John Theurer Cancer Center partners with the Lymphoma Research Foundation and Leukemia Lymphoma Society, among others, to promote education for both professionals and patients through grand rounds and other platforms. These initiatives demonstrate our commitment to sharing advances in lymphoma care with all healthcare providers, ultimately benefiting patients everywhere.
